The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Giglio, Andrea De; Federico, Alessandro Di; Nuvola, Giacomo; Deiana, Chiara; Gelsomino, Francesco

doi:10.1007/s11912-021-01124-9

Cited by 48 publications

(44 citation statements)

References 112 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A limitation of this study is our focus on NSCLC patients who received a single therapy, which is no longer the standard of care ( 45 , 63 , 64 ). However, as anti-PD-1 is well utilized in combination therapy, finding markers that dictate positive responses to anti-PD-1 remains highly useful.…”

Section: Discussionmentioning

confidence: 99%

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths globally. Immune checkpoint blockade (ICB) has transformed cancer medicine, with anti-programmed cell death protein 1 (anti-PD-1) therapy now well-utilized for treating NSCLC. Still, not all patients with NSCLC respond positively to anti-PD-1 therapy, and some patients acquire resistance to treatment. There remains an urgent need to find markers predictive of anti-PD-1 responsiveness. To this end, we performed mass cytometry on peripheral blood mononuclear cells from 26 patients with NSCLC during anti-PD-1 treatment. Patients who responded to anti-PD-1 ICB displayed significantly higher levels of antigen-presenting myeloid cells, including CD9+ nonclassical monocytes, and CD33hi classical monocytes. Using matched pre-post treatment samples, we found that the baseline pre-treatment frequencies of CD33hi monocytes predicted patient responsiveness to anti-PD-1 therapy. Moreover, some of these classical and nonclassical monocyte subsets were associated with reduced immunosuppression by T regulatory (CD4+FOXP3+CD25+) cells in the same patients. Our use of machine learning corroborated the association of specific monocyte markers with responsiveness to ICB. Our work provides a high-dimensional profile of monocytes in NSCLC and links CD33 expression on monocytes with anti-PD-1 effectiveness in patients with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this field, the results of ongoing clinical trials exploring immunotherapy beyond the PD-1-PD-L1 axis will help fill this clinical need. 3…”

Section: Discussionmentioning

confidence: 99%

“…2 Another class of antibodies, including ipilimumab and tremelimumab, have been designed to hit CTLA-4 involved primarily in a checkpoint in activated T cells and antigen-presenting cells. 3 Currently, in the context of non-oncogene-addicted disease, immunecheckpoint inhibitors (ICIs) constitute the upfront standard of care as single agents or in combination with platinum-based chemotherapy (CT). 1 To date, intratumoural expression of PD-L1 is the only biomarker extensively validated within prospective clinical trials to identify patients who will more likely benefit from immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Advanced non-small-cell lung cancer: how to manage non-oncogene disease

Giglio¹,

Federico²,

Deiana³

et al. 2022

DIC

Self Cite

View full text Add to dashboard Cite

The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, has revolutionized the treatment algorithm and the prognosis of patients with NSCLC. In the nononcogene-addicted disease, immune-checkpoint inhibitors, either as single agents or combined with chemotherapy, outperformed standard chemotherapy in both untreated and previously treated patients. However, many patients still do not derive the expected benefit from current treatments. Despite representing the only biomarker currently used in clinical practice to guide treatment selection, PD-L1 expression has been proven an imperfect predictor of immunotherapy outcomes. The evaluation of clinical factors remains essential to detect patients that would benefit the most from a particular treatment approach, but the identification of additional biological and molecular predictive tools is a priority. Herein, we provide a comprehensive though concise review of the current treatment approaches to advanced NSCLC in patients without molecular driver alterations, with an additional focus on special populations, concomitant medications, and other considerations that might be useful for daily clinical practice.

show abstract

“… 78 Other immunotherapeutic agents targeting LAG3, IDO, CD137, and OX40 have been investigated in clinical trials. 354 …”

Section: Immunotherapy For Nsclcmentioning

confidence: 99%

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Yuan

Zhang

2021

MedComm

View full text Add to dashboard Cite

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past decades, despite the rapid development of targeted therapy and immunotherapy in non‐small cell lung cancer (NSCLC). The development and availability of comprehensive genomic profiling make the classification of NSCLC more precise and personalized. Most treatment decisions of advanced‐stage NSCLC have been made based on the genetic features and PD‐L1 expression of patients. For the past 2 years, more than 10 therapeutic strategies have been approved as first‐line treatment for certain subgroups of NSCLC. However, some major challenges remain, including drug resistance and low rate of overall survival. Therefore, we discuss and review the therapeutic strategies of NSCLC, and focus on the development of targeted therapy and immunotherapy in advanced‐stage NSCLC. Based on the latest guidelines, we provide an updated summary on the standard treatment for NSCLC. At last, we discussed several potential therapies for NSCLC. The development of new drugs and combination therapies both provide promising therapeutic effects on NSCLC.

show abstract

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

Cited by 48 publications

References 112 publications

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer

Advanced non-small-cell lung cancer: how to manage non-oncogene disease

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Contact Info

Product

Resources

About